Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

<strong>Trial design</strong> We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blo...

Full description

Bibliographic Details
Main Authors:	Al-Laith, M, Jasenecova, M, Abraham, S, Bosworth, A, Bruce, I, Buckley, C, Ciurtin, C, D'Agostino, M, Emery, P, Gaston, H, Isaacs, J, Filer, A, Fisher, B, Huizinga, T, Ho, P, Jacklin, C, Lempp, H, McInnes, I, Pratt, A, Östor, A, Raza, K, Taylor, P, Van Schaardenburg, D, Shivapatham, D, Wright, A, Vasconcelos, J, Kelly, J, Murphy, C, Prevost, A, Cope, A
Format:	Journal article
Language:	English
Published:	BioMed Central 2019

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Similar Items